IgA VASCULITIS IN THE FORM OF CUTANEOUS PRESENTATION IN A 45-YEAR OLD WOMAN TREATED WITH CORTICOSTEROID: CASE REPORT
DOI:
https://doi.org/10.46311/2318-0579.58.eUJ3780Keywords:
Corticosteroids, Purpura, Schoenlein-Henoch purpura, VasculitisAbstract
Immunoglobulin A vasculitis (IgAV) is known to be a systemic vasculitis of small vessels. Although is possible that this condition sets up in any age group, the epidemiological profile of this disease mostly affects the pediatric population between 2 and 10 years of age. In this sense, this descriptive article aims to report the rare case of an adult patient who evolved with IgAV, presented in a cutaneous form, and treated with corticosteroids. For that, after the patient's free and informed consent, the study was approved by the Research Ethics Committee of the University of Rio Verde (UniRV, Goiás, Brazil), whose Certificate of Presentation for Ethical Consideration is 36621920.0.0000.507. Therefore, it was found that the patient evolved with clinical compatible with IgAV of probable cutaneous involvement due to lesions in the form of purpura and renal involvement, presenting a good therapeutic response with corticosteroid therapy at non-immunosuppressive doses and after 1 year and 3 months of follow-up, there was remission of the clinical picture without new episodes. There are some reports in the literature about the good therapeutic response of this clinical with corticosteroid therapy at non-immunosuppressive doses, however, clinical trials are needed.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 UNINGÁ JOURNAL
This work is licensed under a Creative Commons Attribution 4.0 International License.
I declare/we declare that the text submitted here is original, of my own authorship and does not infringe any type of third party rights. The content is my/our sole responsibility. Possible research involving animals and/or human beings is in accordance with Resolution 196/96 of the National Health Council and its complements. I declare that I am/we are in possession of the written consent of patients and that the research and its procedures were timely and adequately approved by the Ethics Committee of the institution of origin. We further declare that all institutional affiliations and all sources of financial support for the work are duly informed. I certify that there is no commercial or associative interest that represents a conflict of interest related to the submitted work. If there is commercial interest, in addition to the technical and academic ones, in the publication of the article, the information will be reported during the text.
